Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.59 |
| ▸ | NMT1 | P30419 | 4/20 | 0.57 |
| ▸ | NMT2 | O60551 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22397151 | 0.89 | MMP13 (0.49) | MEN1HSP90AA1KMT2AGABRA1GABRG2 | |
| SCHEMBL20944218 | 0.84 | MEN1 (0.57) | MEN1HSP90AA1KMT2AGABRA1GABRG2 | |
| SCHEMBL2652933 | 0.83 | CTSL (0.61) | MEN1KMT2AGABRA2LMNAMAPT | |
| SCHEMBL20944444 | 0.83 | NMT1 (0.56) | MEN1HSP90AA1KMT2AGABRA1GABRG2 | |
| SCHEMBL20944400 | 0.83 | MEN1 (0.56) | MEN1HSP90AA1KMT2AGABRA1GABRG2 | |
| SCHEMBL20944581 | 0.83 | GABRA1 (0.57) | MEN1HSP90AA1KMT2AGABRA1GABRG2 | |
| SCHEMBL22718916 | 0.83 | ALDH1A1 (0.58) | MEN1HSP90AA1KMT2AGABRA1GABRG2 | |
| SCHEMBL163381 | 0.81 | SMN1; SMN2 (0.53) | MEN1KMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL112672 | 0.81 | MEN1 (0.59) | MEN1HSP90AA1KMT2AGABRA1GABRG2 | |
| SCHEMBL9729781 | 0.80 | ALDH1A1 (0.55) | MEN1KMT2AGABRA2LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3704113-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| CN-111295382-A | Bridged bicyclic compounds as modulators of farnesoid X receptors | 百时美施贵宝公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, NR1H2 | MEN1 2553/4885HSP90AA1 2046/4885KMT2A 4610/4885 |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, NR1H2 | MEN1 2553/4885HSP90AA1 2046/4885KMT2A 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.